Penn spinout Apellis received FDA approval for an expanded label for Empaveli®, making it the first treatment authorized to reduce protein in the urine of patients aged 12 and older with rare kidney diseases C3 glomerulopathy (C3G) and primary IC-MPGN (a complement-driven kidney disorder). Empaveli® is based on a compound invented by John Lambris, PhD, the Dr. Ralph and Sallie Weaver Professor of Research Medicine at Penn Medicine. Read more here.